Genenta Science S.p.A.

GNTA · Nasdaq · Italy

Share price · GNTA

$0.98-0.42 (-30.14%) 3M

no price since 3 Nov 2026

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when GNTA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 3 Nov 2026+20.6%
  2. 2 Nov 2026+32.1%
  3. 1 Oct 2026+14.8%

    Nothing announced by GNTA that day or the session before.

  4. 2 Jun 2026+33.3%
  5. 1 Jun 2026+60.2%
  6. 29 May 2026+15.1%
  7. 27 May 2026+37.3%

    Nothing announced by GNTA that day or the session before.

  8. 9 Feb 2026+14.3%

    Nothing announced by GNTA that day or the session before.

  9. 5 Feb 2026-15.4%

    Nothing announced by GNTA that day or the session before.

  10. 30 Jan 2026-15.7%

Share of unusual movement by asset

For each asset, the share of GNTA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—32%
Sessions with no dated event—68%

No dated announcements about its assets since 2 Jul 2024.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
Interferon-alpha2 (myeloid-specific expression) · Interferon-alpha2 (IFN-alpha2) expression in myeloid cellsGene therapy / editing
Glioblastoma

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$3.1M$6.5M+ $27M short-term inv.$1.9M-$7.8M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$5.2M$4.8M+ $8.4M short-term inv.$2.4M-$6.8M operating cash flowreport ↗
2023-FY—$7.0M$4.1M+ $17M short-term inv.$3.1M-$12M operating cash flowreport ↗
2022-FY—$5.6M$32M$2.2M-$7.8M operating cash flowreport ↗
2021-FY—$4.0M$42M$1.6M-$8.2M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-03-30Paracchi Pierluigi · director, Chief Executive Officer, 10% ownerAward / grant (derivative)100,000——Form 4
2026-03-30SLANSKY RICHARD B · Chief Financial OfficerAward / grant (derivative)80,000——Form 4
2026-03-30Mutti Miguel Maria · directorAward / grant (derivative)20,000——Form 4
2026-03-30Sharei Armon · directorAward / grant (derivative)20,000——Form 4
2026-03-30PARACCHI GIACOMOANTONIO · directorAward / grant (derivative)20,000——Form 4
2026-03-30Galimi Francesco · director, CMO& Head of DevelopmentAward / grant (derivative)20,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 11 reporting institutions held 1.0M shares ($696K, 4.4% of shares outstanding).

#InstitutionSharesValue
1Eurizon Capital SGR S.p.A.360,000$242K
2Allianz SE234,050$157K
3AlTi Global, Inc.200,288$135K
4SmartHarvest Portfolios, LLC134,447$90K
5Independent Advisor Alliance37,036$25K
6XTX Topco Ltd24,527$16K
7MORGAN STANLEY15,420$10K
8GAMMA Investing LLC14,288$10K
9Simplicity Wealth,LLC12,211$8K
10UBS Group AG3,107$2K
11Farther Finance Advisors, LLC3$2